EyePoint US Inc. told Massachusetts it will lay off 105 employees in Northbridge and Watertown, according to the state's weekly WARN report. The state received the notice Oct. 20, and the layoffs are scheduled from Dec. 31, 2026, to Jan. 31, 2027. The state report does not split the 105 between the Watertown headquarters and the Northbridge manufacturing site.

The Watertown-based biotech said Oct. 19 that it plans to cut about 53% of its companywide workforce after a second late-stage trial of its lead eye drug did not meet its primary endpoint. EyePoint said its Phase 3 LUCIA trial of Duravyu, an insert placed in the eye to treat wet age-related macular degeneration, did not show vision gains statistically comparable to those of aflibercept, an approved drug. The company said an earlier Phase 3 trial, LUGANO, also missed that endpoint.

The board approved the cuts Oct. 17, according to a company filing with the Securities and Exchange Commission. EyePoint said it will end both wet macular degeneration trials early and focus on Duravyu for diabetic macular edema, with results from two trials in that condition expected in the fourth quarter of 2027.

The company estimated about $9 million in charges for employee separation benefits, including severance. In its Oct. 19 release, EyePoint said it expects the plan to save about $30 million a year and estimated it had about $118 million in cash, cash equivalents and short-term investments as of Sept. 30, 2026. EyePoint's annual report listed 214 employees, all full-time and all in the United States, as of Feb. 27, 2026.

"Decisions involving a reduction in our workforce are exceptionally difficult, and we extend our deepest gratitude to our departing colleagues for their dedication and meaningful contributions," Jay S. Duker, M.D., EyePoint's president and chief executive, said in a statement.

EyePoint said it will run more analyses of the trial data before deciding what comes next for Duravyu in wet macular degeneration.

Sources: Massachusetts WARN weekly report, week ending Oct. 23, 2026; EyePoint, "EyePoint Announces Strategic Prioritization," Oct. 19, 2026; EyePoint, "EyePoint Announces Topline Results from LUCIA," Oct. 19, 2026; EyePoint Form 8-K, filed Oct. 19, 2026; EyePoint 2025 Form 10-K.